BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
Key Highlights
- ➤Bezisterim significantly improved motor and non-motor symptoms in high-inflammation Parkinson’s patients
- ➤Total MDS-UPDRS scores improved -1.23 versus +1.21 for placebo (p=0.0006)
- ➤Bezisterim patients were 6.25-fold more likely to achieve meaningful CBS improvement
- ➤Clinically meaningful worsening risk was approximately 70% lower with bezisterim
- ➤Treatment-emergent adverse events occurred in 39.3% versus 51.7% for placebo
Expert Statements
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“These results provide evidence that an anti-inflammatory treatment can benefit both motor and, importantly, non-motor symptoms of Parkinson’s disease”
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“Because non-motor symptoms remain a significant unmet need, the breadth of activity observed with bezisterim is particularly encouraging for its development as a treatment for early Parkinson’s disease.”
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“In SUNRISE-PD we observed a consistent pattern of improvement across motor symptoms, non-motor symptoms, and daily functioning, with particularly encouraging results among patients with higher baseline platelet counts, a potential marker of systemic inflammation.”
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“We believe these findings provide an important foundation for future studies and support the development of bezisterim as a treatment with the potential not only to provide symptomatic benefit, but also to impact the underlying disease process and potentially slow disease progression.”
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo.
CARSON CITY, Nev., Oct. 20, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of results from the Phase 2 SUNRISE-PD clinical trial evaluating bezisterim in early Parkinson’s patients at the 151st Annual Meeting of the American Neurological Association (ANA), held October 17–20, 2026, in San Diego, California. The study’s abstract was published in Annals of Neurology (Vol. 100, pp. S4–S375, https://doi.org/10.1002%2Fana.78378), in conjunction with the meeting.
Get started
Create a free account to read the full story.